CLINICAL & PIPELINE·Clinical Trial Termination
Infinity Pharmaceuticals' IPI-504 Phase 2 Trial for ALK-Positive NSCLC Terminated Due to Slow Accrual
Infinity Pharmaceuticals, Inc. faces a strategic setback with the termination of its Phase 2 clinical trial (NCT01228435) for IPI-504, an Hsp90 inhibitor, in ALK-positive NSCLC patients. The trial, led by Massachusetts General Hospital, ceased due to slow accrual, having enrolled only three participants. This event impacts future R&D investments and competitive positioning in targeted oncology therapies.
90-Day Activity